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Abstract
Epstein-Barr virus (EBV)-associated B-cell post-transplantation lymphoproliferative disorder (PTLD) is a severe compli-
cation following stem cell transplantation. This is believed to occur as a result of iatrogenic immunosuppression
leading to a relaxation of T-cell control of EBV infection and thus allowing viral reactivation and proliferation of
EBV-infected B-lymphocytes. In support of this notion, reduction of immunosuppressive therapy may lead to
regression of PTLD.
We present a case of an 18-year-old male developing a monomorphic B-cell PTLD 2 months after receiving an
allogenic stem cell transplant for acute lymphoblastic leukemia. Reduction of immunosuppressive therapy led to
regression of lymphadenopathy. Nevertheless, the patient died 3 months afterwards due to extensive graft-vs.-host-
disease and sepsis. As a diagnostic lymph node biopsy was performed only after reduction of immunosuppressive
therapy, we are able to study the histopathological changes characterizing PTLD regression. We observed extensive
apoptosis of blast cells, accompanied by an abundant infiltrate comprising predominantly CD8-positive, Granzyme
B-positive T-cells. This observation supports the idea that regression of PTLD is mediated by cytotoxic T-cells and is
in keeping with the observation that T-cell depletion, represents a major risk factor for the development of PTLD.
Introduction
The Epstein-Barr virus (EBV), a human herpes virus,
was first discovered in 1964 in cultured tumour cells
from Burkitt lymphoma [1]. Subsequently, EBV was
shown to be ubiquitously distributed, infecting over 90%
of the adult human population world wilde. Upon pri-
mary infection, B-cells are immortalized and driven into
proliferation. Viral infection in B-cells usually remains
latent, i.e., infectious virus is not produced, and is char-
acterised by the expression of several viral proteins,
notably EBV-encoded nuclear antigen (EBNA) 2 and
latent membrane protein (LMP) 1, which are thought
to orchestrate virus-induced immortalisation and
proliferation of B-cells. As a consequence, EBV-specific
cytotoxic (CD8-positive) T-cells are generated which
control EBV infection and lead to the establishment of
an asymptomatic life-long virus persistence in memory
B-cells with minimal viral gene expression. This, how-
ever, can change in transplant recipients in whom iatro-
genic immunosuppression leads to a relaxation of T-cell
control of EBV infection allowing the re-emergence of
proliferating EBV-infected B-cells and leading to post-
transplantation lymphoproliferative disorders (PTLDs)
(for review see Hsieh 1999 and Loren 2003 [2,3]).
According to the WHO classification PTLD comprise
five subtypes, i.e., early lesions (plasmacytic hyperplasia
and infectious mononucleosis-like PTLD), polymorphic
PTLD, monomorphic B-cell PTLD, monomorphic
T/NK-cell PTLD and classical Hodgkin lymphoma-like
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proliferations [4] of poly- and monoclonal origin. Risk
factors for the development of a PTLD after HSCT
(human stem cell transplantation) include T-cell deple-
tion, age, HLA-mismatch, specific antilymphocyte anti-
graft-versus-host disease therapies, splenectomy and
HSCT for primary immunodeficiency disorders [2,3].
The treatment options for B-cell PTLDs include
reduction of immunosuppression, antiviral therapy,
interferon alpha therapy, CD20 antibody therapy and
chemotherapy.
In this report, we present a case of EBV-associated
PTLD following allogenic stem cell transplantation for
acute lymphoblastic leukemia with evidence of tumor
regression subsequent to reduction of immunosuppres-
sion, showing for the first time the histopathological
changes within lymph nodes after reduction of
immunosuppression.
Clinical Case
An 18-year-old male patient presented with tiredness,
night sweats, dyspnoea at exercise and shivering. The
blood count showed anemia (Hb 3,1 mmol/l and throm-
bocythopenia (thrombocytes 143/nl). The white blood
cell count and the differential blood smear were normal
(leukocytes 6800/μl: granulocytes 60%; lymphocytes 36%;
monocytes 2%; eosinophils 2%; blasts not detectable).
A diagnosis of acute lymphoblastic leukemia (L2 accord-
ing to the FAB classification) was made based on bone
marrow trephine biopsy showing dense lymphoblastic
infiltrates (about 90%) with a severely reduced residual
haematopoiesis. The tumor cells were positive for CD19
and cytoplasmatic IgM as well as CD10, CD34 and TdT
consistent with ALL. The myeloid marker CD13 was aber-
rantly coexpressed. No expression was observed for CD3.
FACS analysis showed predominantly immature B-lym-
phocytes, strongly positive for CD34 and CD10 confirming
the diagnosis of a common-B-ALL. PCR-analysis revealed
no evidence of BCR-ABL fusion transcripts.
Immediately after diagnosis, primary chemotherapy
was started with dexamethasone, cyclophosphamide and
methotrexate 15 mg intrathecally for 5 days. Subse-
quently, an induction chemotherapy phase I according
to the GMALL 07/2003 protocol (German Multicenter
Study Group for Adult ALL) was performed with dexa-
methasone, vincristine, daunorubicine and asparaginase.
During the induction therapy a prophylactic irradiation
of the central nervous system was performed (24 Gy).
Complete remission was achieved. However, since FACS
analysis of the bone marrow showed a residual com-
mon-B-ALL population of 2%, consolidation therapy
(according to GMALL) was completed and an unrelated
allogenic stem cell donor was identified (HLA-status: A,
B, DRB1, DQB1 identical, C: mismatch).
Eight months after the initial diagnosis, allogenic per-
ipheral stem cell transplantation was performed: the
conditioning regimen consisted of 12Gy total body irri-
tation in 6 fractions with shielding of the lungs (10Gy),
cyclophosphamide dose 60 mg/kg/d at 2 days and ATG
(rabbit) 1000 mg/d = 14,7 mg/kg/d at day -4 to -1
before first PSCT. Graft-versus-host prophylaxis con-
sisted of cyclosporin A, MTX and prednisolon. Whereas
no early complications were noted, mucositis later
required parenteral alimentation. Because of fever of
unknown origin the patient was treated with antibiotics
for 28 days after transplantation, when the patient was
referred to a rehabilitation center.
Seven weeks post-transplantation, the patient devel-
oped fever (up to 39°C) and a rapidly progressing pain-
ful lymphadenopathy at multiple sites (submandibular,
axillar and inguinal). CrP and creatinine increased and
he developed leuko- and thrombocytopenia: He was
therefore was referred to the hospital for further diagno-
sis. Medication at transferral included diflucane® 200
(fluconazol 200 mg) twice a day i.v. and ceftriaxone 2 g
i.v. per day. The dose of sandimmune® optoral was
reduced from 150 mg to 100 mg upon arrival at the
hospital. An infection with EBV and a reactivation of
CMV could be confirmed with PCR-analysis of periph-
eral blood and after medication with zovirax® (acyclovir),
cymevene® (gancyclovir) was used for therapy for 9 days
(was heißt das genau?). Subsequently, the CMV and
EBV-PCR was negative again.
Atypical lymphocytes were found in the peripheral
blood. FACS- analysis showed no evidence of recurrent
pre-B-ALL suggesting virus-induced alterations. A high
percentage of activated T-cells and a marked shift of
T-cell subpopulations (CD4/CD8: 0,03) were conspicu-
ous. Histopathological examination of bone marrow tre-
phine biopsy showed a moderately hypocellular bone
marrow with borderline maturation abnormalities of
erythro- and megakaryopoesis, reactive eosinophilia and
increased siderin in histiocytic cells. No lymphocytic or
lymphoblastic infiltrates were detectable. Overall, the
histological picture was considered to be consistent with
drug-induced bone marrow toxicity.
CT-scan showed splenic enlargement and cervical,
axillary, inguinal and abdominal lymphadenopathy. The
brain was normal with no evidence of tumor infiltration.
Cervical lymph node biopsy was performed 1 week
after transferral to the hospital and 1 week subsequent
to the reduction of immunosuppressive therapy. This
revealed complete effacement of lymph node architec-
ture (fig. 1a-c) due to infiltration by CD20-positive lym-
phoid blasts (Fig. 1d) with high proliferative activity
(Mib-1 80-90%: fig. 1l). The vast majority of infiltrating
cells were EBV-positive as demonstrated by EBER-speci-
fic in situ hybridisation (not shown). Scattered blast
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(fig. 1h), indicating a type III of EBV latency. PCR analy-
sis showed a monoclonal rearrangement of the immuno-
globulin heavy chain gene locus. Thus, the diagnosis of a
monoclonal, monomorphic EBV-associated B-cell PTLD
was made. Of note, focal areas of necrosis (fig. 1a: arrow
head) and extensive apoptotic activity with many macro-
phages engulfing apoptotic nuclear bodies (fig. 1b, c, e,
f) were found. The B-cell proliferation was accompanied
by an extensive CD3-positive T-cell infiltrate (fig. 1j)
consisting predominantly of CD8/perforin/granzymeB-
positive cytotoxic T-cells (fig. 1k-m) with only very few
CD4 positive cells present (fig. 1n). Chimerism testing
showed that T-and B-cells, found in the lymph node,
were 100% of donor origin.
CT-scans taken 1 week after biopsy showed regression
of lymphadenopathy. Virological testing was finally
n e g a t i v ef o rE B Va n dC M V .T h ep a t i e n ta c h i e v e dc o m -
plete remission and was discharged 1 month after initial
development of lymphadenopathy.
Two months later the patient was referred again to
the hospital with diarrhoea and emesis, fever and
Figure 1 On conventional HE staining a lymph node with vanished lymph node structure and focal necrosis and perinodal lymphatic
infiltrates were seen (a). At higher magnification (b, c), a blastic infiltrate with strong apoptotic activity and many macrophages engulfing
apoptotic nuclear bodes were visible. Immunolabeling confirmed the B-cellular lineage of most blastic cells (d: CD20) with macrophages cells
lying in between (e+f: CD68). Part of the blastic cells was positive for EBNA2 (g) and EBV late membrane antigen (h: LMP). Overall, there was a
high proliferative activity (i: Mib-1 positivity in about 80-90% of B-blasts). Additionally, a lot of CD3 (j)/CD8 (k) positive T-cells were interspersed,
with hardly any CD4-positive T-helper cells identifiable (l). The T-cells were positive for perforin (m) and granzyme B (n). (a-c: hematoxylin eosin
stainings; d-n: immunostainings with the antibodies indicated above) (magnification bars: a: 500 μm; b: 100 μm; c: 22 μm; d, e, g, i-n: 50 μm; f, h,
l: 40 μm).
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therapy the general condition of the patient worsened.
He developed septicaemia and he became somnolent
due to encephalopathy. He developed severe pulmonary
oedema and died 12 months after initial diagnosis of
ALL and 3 months after initial diagnosis of PTLD due
to multi-organ failure.
At post-mortem examination, no residues of ALL or
PTLD were found. The bone marrow was significantly
hypocellular with a dramatic reduction of all three
hematopoietic cell lines. Evidence of GvHD was found
in stomach, small intestine and colon, and there were
disseminated hyaline micro-thrombi in lungs and myo-
cardium. Petechial bleeding was seen in small intestine,
ileum and colon and there was extensive hemorrhage in
the spleen. In addition, there was biventricular cardiac
hypertrophy and evidence of congestive heart failure.
Discussion
EBV-associated PTLD is an important complication of
stem cell transplantation. In healthy individuals, primary
EBV infection induces a virus-driven B-cell proliferation
which may manifest clinically as infectious mononucleo-
sis and which eventually is controlled by the develop-
ment of a virus-specific T-cell immunity. This is
directed against virus-encoded lytic and latent proteins
and allows the establishment of life-long virus persis-
tence in memory B-cells.
While virus persistence remains asymptomatic in the
vast majority of individuals, occasionally EBV-associated
tumours may develop, mostly of lymphoid origin. It is
generally assumed that some degree of failure of the
immune system to control EBV infection is involved in
the pathogenesis of these neoplasms [5]. This failure
may be in the microenvironment of the tumour cells.
E.g., it is assumed that modulation of local immune
reactions by cytokines produced in the tumour cells
contributes to the development of EBV-associated
Hodgkin lymphoma. On the other hand, failure of EBV-
specific immunity may be systemic, as in transplant reci-
pients subjected to iatrogenic immunosuppression [5].
The notion that failure of T-cell control of EBV infec-
tion is a crucial factor in the pathogenesis of PTLD is
supported by several observations. PTLD cells frequently
express EBV-encoded latent proteins, including EBNA2,
which are recognised by EBV-specific T-cells in immu-
nocompetent individuals [6]. Moreover it has long been
known that PTLDs may regress upon reduction or with-
drawal of immunosuppressive therapy [7]. Also, EBV-
specific cytotoxic T-cells may induce regression of the
outgrowth of EBV-transformed B-cells in vitro and this
effect is abolished by cyclosporine A [8]. Finally, adop-
tive transfer of EBV-specific T-cells has proved success-
ful in the treatment and prevention of PTLD [9].
Here we present, to our knowledge, the first descrip-
tion of the histopathological features of PTLD regression
following reduction of immunosuppressive therapy.
These were characterised by two main features. We
demonstrate an intense infiltration of the affected lymph
node by cytotoxic T-cells expressing CD8, perforin, and
granzymeB. In addition, we observed extensive apoptosis
of blast cells. The resulting apoptotic nuclear bodies
were phagocytosed by macrophages. The latter feature is
reminiscent of, e. g., Burkitt lymphoma and in germinal
centre reactions, where a a high cellular turnover is
accompanied by intense apoptotic activity. Although we
cannot prove this directly, in the context of previous
studies cited above, our results strongly suggest that
apoptotic regression of the neoplastic EBV-positive
B-cells was triggered by the re-emergence of EBV-speci-
fic T-cells in this case. This notion is well in line with
current understanding of EBV-specific T-cell immunity
[10]. In contrast, e. g. in Burkitt lymphoma a high spon-
taneous apoptotic rate is observed in the absence of
cytotoxic T-cells. This might be related to the absence
of antiapopotic factors such as bcl-2, which typically is
not expressed in Burkitt lymphoma. Similarly, in physio-
logical germinal centre reactions, in the absence of bcl-2
expression apoptosis is triggered by a lack of survival
signals rather than cytotoxic activity of T-cells.
This role of cytotoxic T-cells in the control of EBV
infection explains, why T-cell depletion via antithymo-
cyte globulin or anti-CD3 monoclonal antibodies repre-
sents a major risk factor for the development of EBV-
associated PTLD [4,11-13]. As the use of HLA-mis-
matched donor transplants usually requires more inten-
sive immunosuppression, this additionally increases the
risk for developing PTLD. Also, children and teenagers
are at high risk of developing PTLD [14], most likely
because an adequate primary immune response to EBV
infection cannot be mounted under immunosuppressive
therapy and because patients of this age group are fre-
quently EBV seronegative before transplantation [15].
Although regression of PTLD following reduction or
withdrawal of immunosuppressive therapy has been
reported previously, the prognosis generally remains
poor and treatment now includes rituximab and che-
motherapy [16,17]. In our case, reduction of immuno-
suppression without further treatment led to a
reduction of lymphadenopathy with full clinical remis-
sion accompanied by the development of GvHD.
Patients with PTLD following stem cell transplantation
usually die from progressive EBV-associated lymphopro-
liferation, sepsis, severe GvHD or relapse of the underly-
ing haematological malignancy [18]. In our case,
combined sepsis and GvHD were the leading causes of
death and post mortem examination confirmed com-
plete remission of PTLD.
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stem cell transplantation with complete remission fol-
lowing reduction of immunosuppressive therapy. We
were able to show for the first time to our knowledge
the histomorphological features occurring in PTLD
lymph nodes in this scenario which are characterised by
apoptotic cell death of EBV-infected B-blasts triggered
by cytotoxic-T-cells.
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